PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32118594-0 2020 Prognostic and Predictive role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study. Folfox protocol 147-153 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 34-79 33468383-0 2021 Predictive value of KRAS mutation & excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen. Folfox protocol 153-159 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-73 33468383-0 2021 Predictive value of KRAS mutation & excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen. Folfox protocol 153-159 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 75-80 26161376-0 2015 ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting. Folfox protocol 33-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 31815582-14 2020 For all patients and for those with low ERCC1 expression, FOLFOX was superior in efficacy to IT. Folfox protocol 58-64 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 40-45 28608017-0 2017 Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. Folfox protocol 134-140 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-49 28608017-8 2017 CONCLUSIONS: ERCC1 overexpression is associated with a poor preoperative CRT response in patients with rectal cancer receiving FOLFOX-based preoperative CRT. Folfox protocol 127-133 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 26083491-8 2015 The combined low expression of ERCC1/TS was predictive of response in patients treated with FOLFOX (40% vs. 91%, RR 2.3, Fisher"s exact test p = 0.03, n = 27), but not with FOLFIRI (71% vs. 71%, RR 1.0, Fisher"s exact test p = 1, n = 14). Folfox protocol 92-98 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-36 26161376-1 2015 PURPOSE: The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients. Folfox protocol 136-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 55-100 26161376-1 2015 PURPOSE: The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients. Folfox protocol 136-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 102-107 24847383-6 2014 CONCLUSION: The association of ERCC1 and XRCC1 polymorphisms may influence the prognosis of stage III colon cancer patients treated with FOLFOX adjuvant chemotherapy. Folfox protocol 137-143 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-36 24318989-0 2014 Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Folfox protocol 99-105 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 24318989-10 2014 This study reported a carriage of ERCC1 rs11615, and rs2298881 polymorphism can be used as a predictor of response to folinic acid/5-fluorouracil (5-FU)/oxaliplatin (FOLFOX)-based chemotherapy in gastric cancer patients. Folfox protocol 166-172 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 34-39 23996617-0 2013 Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. Folfox protocol 110-118 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 23996617-7 2013 CONCLUSIONS: ERCC1 overexpression is an important predictor of early failure in patients with stage III CRC administrating FOLFOX-4 adjuvant chemotherapy and this marker may help identify patients who would benefit from intensive follow-up and enhance therapeutic programs. Folfox protocol 123-131 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 24125975-11 2013 Determination of ERCC1 mRNA and protein levels may be beneficial in predicting the response and outcome of FOLFOX-4 therapy in gastric cancer. Folfox protocol 107-115 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 17-22 19068092-0 2009 ERCC1 codon 118 C T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Folfox protocol 81-89 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 19068092-3 2009 A marked increase of ERCC1 protein expression levels was also noted in patients with C/T or T/T genotypes (70%vs 20%; P < 0.01), which was associated with significantly lower response to FOLFOX-4 (36.4%vs 57.5%; p = 0.01), and shorter progression-free (7 months vs 13 months; P < 0.01) and overall (16 months vs 25 months; P < 0.01) survival times. Folfox protocol 190-198 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 21-26 23169295-10 2012 In validation study, ERCC1 and DPD but not TOP1 expressions in cancer cells were significantly higher in FOLFOX (oxaliplatin, folinic acid, and 5-FU)-treated patients (N=24) than nontreated patients (N=21). Folfox protocol 105-111 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 21-26 22214010-0 2011 [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)]. Folfox protocol 39-45 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 77-82 21057378-8 2011 CONCLUSION: The genetic polymorphisms of ERCC1 and XRCC1 may be useful in predicting clinical outcome in Taiwanese mCRC patients treated with FOLFOX-4. Folfox protocol 142-150 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46